

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

100

1

Complete if Known

Application Number	10/510,627
§ 371(c) Date	June 20, 2005
Int'l. Filing Date	April 9, 2003
First Named Inventor	Kiyoichi ANDO et al.
Art Unit	1644
Examiner Name	Michael A. BELYAVSKYI
Attorney Docket Number	09617.0001-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
		WO 01/53500 A1	07-26-2001	HYSEQ, INC.		

NON-PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		HIRAKOYA et al., 1987, "Monoclonal antibodies against human hematopoietic survival and growth factor," <i>Biomed. Biochim. Acta</i> , 46(5): 419-427.	
		HIRAKOYA et al., 2001, "Stem cell growth factor: <i>in situ</i> hybridization analysis on the gene expression, molecular characterization and <i>in vitro</i> proliferative activity of a recombinant preparation on primitive hematopoietic progenitor cells," <i>The Hematology Journal</i> , 2: 307-315.	
		ITO et al., 2003, "Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation," <i>Bone Marrow Transplantation</i> , 32: 391-398.	
		Supplementary European Search Report issued in EP App. No. 03 74 5988 dated May 30, 2007, 3 pages.	

Examiner
Signature _____ Date
Considered _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.